Verastem, Inc.

Verastem Oncology is a biopharmaceutical company dedicated to the development and commercialization of novel medicines for patients diagnosed with RAS/MAPK pathway-driven cancers. Headquartered in Needham, Massachusetts, the company's mission is to ensure that cancer patients have access to treatment options, fostering hope through innovative therapies.

The company's key product is AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets), an FDA-approved combination therapy for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. Verastem Oncology's pipeline is focused on small molecule drugs that inhibit critical signaling pathways in cancer, including RAF/MEK inhibition (avutometinib), FAK inhibition (defactinib), and KRAS G12D inhibition (VS-7375). These investigational therapies are being evaluated for various solid tumors, such as LGSOC, pancreatic cancer, non-small cell lung cancer, and colorectal cancer.

In April 2026, Verastem Oncology launched its "Reimagine Recurrent LGSOC" campaign to raise awareness and encourage earlier use of AVMAPKI® FAKZYNJA® CO-PACK. The company also presented two-year median follow-up data for this combination therapy at the SGO 2026 Annual Meeting. Having transitioned to a commercial-stage company in 2025, Verastem reported preliminary net product revenues of approximately $30.9 million for AVMAPKI® FAKZYNJA® CO-PACK for the full year 2025. Leadership changes in December 2025 saw Dan Paterson continue as President and CEO, with Michael Kauffman appointed President of Development and John Johnson as Chairman of the Board. The company continues to advance its clinical development program for VS-7375, a potential best-in-class oral KRAS G12D inhibitor.

Latest updates

Verastem Launches Campaign for Niche Ovarian Cancer Treatment Amid Accelerated Approval Scrutiny

Event summary

  • Verastem Oncology launched a marketing campaign, 'Reimagine Recurrent Low-Grade Serous Ovarian Cancer,' to promote its AVMAPKI® FAKZYNJA® CO-PACK treatment.
  • The treatment is the first FDA-approved therapy specifically for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), affecting approximately 30% of LGSOC patients.
  • AVMAPKI FAKZYNJA CO-PACK received accelerated FDA approval on May 8, 2025, contingent on confirmatory trial results.
  • The campaign aims to educate healthcare professionals (HCPs) and patients, addressing a historical lack of tailored resources for this rare cancer.

The big picture

Verastem's strategy highlights the growing trend of targeting niche cancer subtypes with precision therapies, capitalizing on unmet medical needs. The accelerated approval pathway, while offering faster access to treatment, introduces heightened regulatory risk and necessitates rigorous post-approval data generation. The company's focus on the RAS/MAPK pathway underscores the broader industry effort to overcome drug resistance in cancer treatment, a persistent challenge with significant commercial implications.

What we're watching

Regulatory Risk
The accelerated approval status means Verastem must demonstrate clinical benefit in the RAMP 301 confirmatory trial; failure to do so could lead to market withdrawal and significantly impact valuation.
Market Adoption
The campaign's success hinges on driving adoption among HCPs and patients, given the rare nature of LGSOC and potential challenges in identifying eligible candidates.
Competitive Landscape
While currently the only approved treatment, the emergence of alternative therapies targeting the RAS/MAPK pathway could erode Verastem's market share and pricing power.
CID: 3696